Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma

NCT00987493 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

BIOLOGICAL: rituximab
DRUG: bendamustine hydrochloride
DRUG: lenalidomide

Sponsor

Swiss Cancer Institute